Pell Bio-Med Technology Co., Ltd.
Pell Bio-Med Technology Co., Ltd., a biomedical company, engages in the development of cell culture technologies and techniques for therapeutic applications. Its commercial products include good tissue practice laboratory infrastructure, adipose-derived stem cells (ADSC) for regenerative medicine, and CIK and DC-CIK against cancers. The company also develops medicines for various types of cancers… Read more
Pell Bio-Med Technology Co., Ltd. (6949) - Net Assets
Latest net assets as of September 2025: NT$1.23 Billion TWD
Based on the latest financial reports, Pell Bio-Med Technology Co., Ltd. (6949) has net assets worth NT$1.23 Billion TWD as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$1.62 Billion) and total liabilities (NT$385.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$1.23 Billion |
| % of Total Assets | 76.19% |
| Annual Growth Rate | 78.81% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 111.9 |
Pell Bio-Med Technology Co., Ltd. - Net Assets Trend (2021–2024)
This chart illustrates how Pell Bio-Med Technology Co., Ltd.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Pell Bio-Med Technology Co., Ltd. (2021–2024)
The table below shows the annual net assets of Pell Bio-Med Technology Co., Ltd. from 2021 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | NT$1.29 Billion | +8.87% |
| 2023-12-31 | NT$1.18 Billion | +45.03% |
| 2022-12-31 | NT$814.60 Million | +262.26% |
| 2021-12-31 | NT$224.87 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Pell Bio-Med Technology Co., Ltd.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 101830200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | NT$583.95 Million | 49.49% |
| Other Components | NT$1.80 Billion | 152.83% |
| Total Equity | NT$1.18 Billion | 100.00% |
Pell Bio-Med Technology Co., Ltd. Competitors by Market Cap
The table below lists competitors of Pell Bio-Med Technology Co., Ltd. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Top Resource Conservation Engineering Co Ltd
SHE:300332
|
$507.68 Million |
|
Beijing Hualu Baina Film TV
SHE:300291
|
$507.72 Million |
|
Midland States Bancorp Inc
NASDAQ:MSBIP
|
$507.98 Million |
|
Gold Royalty Corp.
NYSE MKT:GROY
|
$508.32 Million |
|
Jiangxi Ganneng Co Ltd
SHE:000899
|
$507.45 Million |
|
MorningStar Partners, L.P.
NYSE:TXO
|
$507.44 Million |
|
MedCap AB (publ)
ST:MCAP
|
$507.41 Million |
|
Si-Bone Inc
NASDAQ:SIBN
|
$507.40 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Pell Bio-Med Technology Co., Ltd.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,170,210,000 to 1,179,924,000, a change of 9,714,000 (0.8%).
- Net loss of 389,415,000 reduced equity.
- New share issuances of 331,171,000 increased equity.
- Other factors increased equity by 67,958,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-389.42 Million | -33.0% |
| Share Issuances | NT$331.17 Million | +28.07% |
| Other Changes | NT$67.96 Million | +5.76% |
| Total Change | NT$- | 0.83% |
Book Value vs Market Value Analysis
This analysis compares Pell Bio-Med Technology Co., Ltd.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 27.75x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 84.95x to 27.75x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | NT$6.76 | NT$574.00 | x |
| 2022-12-31 | NT$20.42 | NT$574.00 | x |
| 2023-12-31 | NT$25.30 | NT$574.00 | x |
| 2024-12-31 | NT$20.68 | NT$574.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Pell Bio-Med Technology Co., Ltd. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -33.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1983.67%
- • Asset Turnover: 0.01x
- • Equity Multiplier: 1.48x
- Recent ROE (-33.00%) is above the historical average (-44.96%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -84.03% | -1351.93% | 0.04x | 1.75x | NT$-211.44 Million |
| 2022 | -28.73% | -1341.32% | 0.02x | 1.30x | NT$-310.22 Million |
| 2023 | -34.08% | -2211.26% | 0.01x | 1.21x | NT$-515.78 Million |
| 2024 | -33.00% | -1983.67% | 0.01x | 1.48x | NT$-507.41 Million |
Industry Comparison
This section compares Pell Bio-Med Technology Co., Ltd.'s net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,057,086,200
- Average return on equity (ROE) among peers: 8.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Pell Bio-Med Technology Co., Ltd. (6949) | NT$1.23 Billion | -84.03% | 0.31x | $507.62 Million |
| Synbio Tech Inc. (1295) | $863.17 Million | 18.53% | 0.78x | $21.14K |
| Apex Biotechnology Corp (1733) | $1.92 Billion | 19.33% | 0.42x | $65.42 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $1.77 Billion | 2.60% | 1.02x | $129.70 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $122.27 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.62 Billion | 0.90% | 0.98x | $40.94 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $1.10 Billion | 14.01% | 0.66x | $45.00 Million |
| Level Biotechnology (3118) | $542.40 Million | 10.78% | 0.50x | $22.42 Million |
| GenMont Biotech Inc (3164) | $737.87 Million | 20.00% | 0.85x | $30.93 Million |
| Medigen Biotechnology (3176) | $650.39 Million | 0.00% | 0.08x | $90.59 Million |
| Sagittarius Life Science (3205) | $531.71 Million | -16.25% | 0.27x | $56.62 Million |